日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Atrial Fibrillation in Athletes: Mechanisms, Management, and Future Directions

运动员心房颤动:机制、治疗及未来方向

Alameh, Ibrahim; Al Fout, Ghina; Ezekowitz, Michael D; Kamareddine, Mohammed

Emergency department visit for atrial fibrillation: sex differences in treatment and outcomes in the Global RE-LY AF Registry

因房颤就诊急诊科:全球 RE-LY AF 注册研究中治疗和结局的性别差异

Johnson, Linda S; Jiang, Yuxuan; Luu, Judy; Van Gelder, Isabelle C; Atzema, Clare; Conen, David; Kloosterman, Marielle; Armaganijan, Luciana; Connolly, Stuart J; Ezekowitz, Michael D; Wallentin, Lars; Johansson, Isabelle; McIntyre, William F; Oldgren, Jonas; Healey, Jeffrey S

Estimating Vitamin K Antagonist Anticoagulation Benefit in People With Atrial Fibrillation Accounting for Competing Risks: Evidence From 12 Randomized Trials

评估维生素K拮抗剂抗凝治疗对房颤患者的益处,并考虑竞争风险:来自12项随机试验的证据

Shah, Sachin J; van Walraven, Carl; Jeon, Sun Young; Boscardin, John; Hobbs, F D Richard; Connolly, Stuart J; Ezekowitz, Michael D; Covinsky, Kenneth E; Fang, Margaret C; Singer, Daniel E

The ATHERO-AF Study: A Need to Optimize AF Management in an Environment of Medical Advancement

ATHERO-AF 研究:在医疗进步的环境下,优化房颤管理势在必行

Ezekowitz, Michael D; Alameh, Ibrahim; Kamareddine, Mohammed

Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation.

利用多标志物筛查来识别与房颤患者心血管死亡相关的生物标志物

Pol Tymon, Hijazi Ziad, Lindbäck Johan, Oldgren Jonas, Alexander John H, Connolly Stuart J, Eikelboom John W, Ezekowitz Michael D, Granger Christopher B, Lopes Renato D, Yusuf Salim, Siegbahn Agneta, Wallentin Lars

Drug Interactions Affecting Oral Anticoagulant Use

影响口服抗凝剂使用的药物相互作用

Mar, Philip L; Gopinathannair, Rakesh; Gengler, Brooke E; Chung, Mina K; Perez, Arturo; Dukes, Jonathan; Ezekowitz, Michael D; Lakkireddy, Dhanunjaya; Lip, Gregory Y H; Miletello, Mike; Noseworthy, Peter A; Reiffel, James; Tisdale, James E; Olshansky, Brian

Residual stroke risk despite oral anticoagulation in patients with atrial fibrillation

即使接受口服抗凝治疗,房颤患者仍存在残余卒中风险

Carlisle, Matthew A; Shrader, Peter; Fudim, Marat; Pieper, Karen S; Blanco, Rosalia G; Fonarow, Gregg C; Naccarelli, Gerald V; Gersh, Bernard J; Reiffel, James A; Kowey, Peter R; Steinberg, Benjamin A; Freeman, James V; Ezekowitz, Michael D; Singer, Daniel E; Allen, Larry A; Chan, Paul S; Pokorney, Sean D; Peterson, Eric D; Piccini, Jonathan P

Testing the feasibility of operationalizing a prospective, randomized trial with remote cardiac safety EKG monitoring during a pandemic

在疫情期间开展一项前瞻性随机试验,并进行远程心脏安全心电图监测,以检验其可行性。

Liu, Hans H; Ezekowitz, Michael D; Columbo, Michele; Khan, Oneib; Martin, Jack; Spahr, Judith; Yaron, David; Cushinotto, Lisa; Kapelusznik, Luciano

Retrospective Comparison of Patients ≥ 80 Years With Atrial Fibrillation Prescribed Either an FDA-Approved Reduced or Full Dose Direct-Acting Oral Anticoagulant

回顾性比较年龄≥80岁且患有房颤的患者接受FDA批准的减量或全剂量直接口服抗凝剂治疗的效果

Taoutel, Roy; Ezekowitz, Michael D; Chaudhry, Usman A; Weber, Carly; Hassan, Dana; Gracely, Ed J; Kamareddine, Mohammed H; Horn, Benjamin I; Harper, Glenn R

Evaluation of the prognostic value of GDF-15, ABC-AF-bleeding score and ABC-AF-death score in patients with atrial fibrillation across different geographical areas

评估GDF-15、ABC-AF出血评分和ABC-AF死亡评分在不同地理区域房颤患者中的预后价值

Pol, Tymon; Hijazi, Ziad; Lindbäck, Johan; Alexander, John H; Bahit, M Cecilia; De Caterina, Raffaele; Eikelboom, J W; Ezekowitz, Michael D; Gersh, Bernard J; Granger, Christopher B; Hylek, Elaine M; Lopes, Renato; Siegbahn, Agneta; Wallentin, Lars